Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levenson, A. S.
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levenson, A. S.
Right arrow Articles by Jordan, V. C.
[Cancer Research 62, 4419-4426, August 1, 2002]
© 2002 American Association for Cancer Research

Molecular Biology and Genetics

Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor1

Anait S. Levenson2, Kristen M. Svoboda, Katherine M. Pease, Scott A. Kaiser, Bin Chen, Laura A. Simons, Borko D. Jovanovic, Patricia A. Dyck and V. Craig Jordan

Robert H. Lurie Comprehensive Cancer Center [A. S. L., K. M. S., K. M. P., S. A. K., B. C., L. A. S., V. C. J.], Department of Preventive Medicine [B. D. J.], Center for Genetic Medicine and Department of Computer Science [P. A. D.], The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611

Selective Estrogen Receptor Modulators (SERMs) are a new class of drugsthat bind to estrogen receptor (ER) and elicit agonistic or antagonistic responses, depending on the target tissue. We have developed an in vitro system in which some SERMs (4-hydroxytamoxifen and resveratrol) demonstrate estrogenic response through wild-type (wt) ER, whereas others (raloxifene and GW7604) remain antiestrogenic. This system mimics the tamoxifen-resistant phenotype in clinic, when resistant tumors contain wtER. We used Atlas cDNA arrays to study gene expression profiles after ER activation by different SERMs in MDA-MB-231 human breast cancer cells stably transfected with wtER. Cells were treated with estradiol, four different SERMs, and the pure antiestrogen ICI 182,780. The obtained expression data were analyzed using GeneSpring software. Real-time reverse transcription-PCR was used to verify the array data. Our results showed that treatment with various compounds altered the expression of a diverse group of genes, revealing sets of overlapping genes that may represent a complex network of genes of interrelated signal transduction pathways.

Sets of "agonistic" and "antagonistic" genes were identified on the basis of the known response to different SERMs. Further analysis of selected sets of genes revealed functionally related group of genes in each set, encoding proteins that were related to cell proliferation, survival, and apoptosis. Flow cytometry data indicated an antiapoptotic activity in cells treated with agonists versus apoptotic activity in cells treated with antagonists. A model for estradiol-like (survival) and antiestrogen-like (apoptosis) activities of SERMs on the basis of their gene expression profiles is suggested.




This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
N. S. Wickramasinghe, T. T. Manavalan, S. M. Dougherty, K. A. Riggs, Y. Li, and C. M. Klinge
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells
Nucleic Acids Res., May 1, 2009; 37(8): 2584 - 2595.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
F. Wu, I. Ivanov, R. Xu, and S. Safe
Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studies
J. Mol. Endocrinol., January 1, 2009; 42(1): 19 - 33.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. M. Klinge, N. S. Wickramasinghe, M. M. Ivanova, and S. M. Dougherty
Resveratrol stimulates nitric oxide production by increasing estrogen receptor {alpha}-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells
FASEB J, July 1, 2008; 22(7): 2185 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. J. Higgins, S. Liu, M. Abdelrahim, K. Vanderlaag, X. Liu, W. Porter, R. Metz, and S. Safe
Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17{beta}-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins
Mol. Endocrinol., February 1, 2008; 22(2): 388 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Kininis, B. S. Chen, A. G. Diehl, G. D. Isaacs, T. Zhang, A. C. Siepel, A. G. Clark, and W. L. Kraus
Genomic Analyses of Transcription Factor Binding, Histone Acetylation, and Gene Expression Reveal Mechanistically Distinct Classes of Estrogen-Regulated Promoters
Mol. Cell. Biol., July 15, 2007; 27(14): 5090 - 5104.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K.-C. Leung, J. Brce, N. Doyle, H. J. Lee, G. M. Leong, K. Sjogren, and K. K. Y. Ho
Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases
Endocrinology, May 1, 2007; 148(5): 2417 - 2423.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Zwart, A. Griekspoor, M. Rondaij, D. Verwoerd, J. Neefjes, and R. Michalides
Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor {alpha}
Mol. Cancer Ther., May 1, 2007; 6(5): 1526 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. M. E. Harvell, J. K. Richer, D. C. Allred, C. A. Sartorius, and K. B. Horwitz
Estradiol Regulates Different Genes in Human Breast Tumor Xenografts Compared with the Identical Cells in Culture
Endocrinology, February 1, 2006; 147(2): 700 - 713.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J G Moggs, T C Murphy, F L Lim, D J Moore, R Stuckey, K Antrobus, I Kimber, and G Orphanides
Anti-proliferative effect of estrogen in breast cancer cells that re-express ER{alpha} is mediated by aberrant regulation of cell cycle genes
J. Mol. Endocrinol., April 1, 2005; 34(2): 535 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Becker, A. Sommer, J. R. Kratzschmar, H. Seidel, H.-D. Pohlenz, and I. Fichtner
Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM
Mol. Cancer Ther., January 1, 2005; 4(1): 151 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
V. Bourdeau, J. Deschenes, R. Metivier, Y. Nagai, D. Nguyen, N. Bretschneider, F. Gannon, J. H. White, and S. Mader
Genome-Wide Identification of High-Affinity Estrogen Response Elements in Human and Mouse
Mol. Endocrinol., June 1, 2004; 18(6): 1411 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
M. Kian Tee, I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R. J. Christy, K. R. Yamamoto, and D. C. Leitman
Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors {alpha} and {beta}
Mol. Biol. Cell, March 1, 2004; 15(3): 1262 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Frasor, F. Stossi, J. M. Danes, B. Komm, C. R. Lyttle, and B. S. Katzenellenbogen
Selective Estrogen Receptor Modulators: Discrimination of Agonistic versus Antagonistic Activities by Gene Expression Profiling in Breast Cancer Cells
Cancer Res., February 15, 2004; 64(4): 1522 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. M. Sakamoto, K. B. Kim, R. Verma, A. Ransick, B. Stein, C. M. Crews, and R. J. Deshaies
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Mol. Cell. Proteomics, December 1, 2003; 2(12): 1350 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. R. Coser, J. Chesnes, J. Hur, S. Ray, K. J. Isselbacher, and T. Shioda
Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray
PNAS, November 25, 2003; 100(24): 13994 - 13999.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.